The Readout Loud
STAT
Add to My Podcasts
Episodes
About
Reviews
Promote
Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data
24 minutes
Posted Jul 26, 2018 at 8:19 pm.
0:00
24:58
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?
Previous
Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season
Next
Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest
← See all 425 episodes of The Readout Loud
